A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma

Journal of Immunotherapy

Volumn 28, Issue 6, 2005, Pages 576-581

  Koulova, Lydia ^a   Novik, Yelena ^a   Caliendo, Geralyn ^a   Wiernik, Peter ^a   Dutcher, Janice ^a  

^a OUR LADY OF MERCY MEDICAL CENTER   (United States)

Author keywords

Granulocyte macrophage colony stimulating factor; Immunotherapy; Interleukin 2; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CIMETIDINE; CIPROFLOXACIN; CREATININE; DIPHENHYDRAMINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDOMETACIN; INTERLEUKIN 12; INTERLEUKIN 2; LIVER ENZYME; PARACETAMOL; PETHIDINE; RANITIDINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; UREA;

ADULT; AGED; AGITATION; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFECT; FATIGUE; FEMALE; FEVER; HEART ATRIUM FIBRILLATION; HUMAN; HYPOTENSION; INOPERABLE CANCER; KIDNEY CARCINOMA; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; METASTASIS; NEUROLOGIC DISEASE; OLIGURIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 27444443754     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000177998.57713.c9     Document Type: Article

References (32)

1. Glaspy JA. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002;29(Suppl 7):41-46.
2. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:668-696.
3. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin 2, recombinant interferon alpha-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998;338:1272-1278.
4. Fisher RI, Rosenberg SA, Fyfe G. Long term survival update for high dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(Suppl 1):S55-S57.
5. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alpha-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol. 1993;9:1809-1816.
6. Ravaud A, Negrier S, Cany L, et al. Subcutaneous low-dose recombinant IL-2 and alpha-interferon in patients with metastatic renal cell carcinoma. Br J Cancer. 1994;69:1111-1114.
7. Dutcher JP, Fisher RI, Weiss G, et al. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow up of the Cytokine Working Group Study. Cancer J Sci Am. 1997;3:142-143.
8. McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004;4:455-468.
9. Atkins MB, Regan M, McDermott DF. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV carcinoma. Clin Cancer Res. 2004;10(Suppl):6342S-6346S.
10. Dutcher JP, Logan T, Gordon M, et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res. 2000;6:3442-3450.
11. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin 2 versus subcutaneous interleukin 2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
12. Yang J, Topalian S, Parkinson D, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994;12:1572-1576.
13. Yang J, Sherry R, Steinberg S, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
14. Stewart-Akers A, Cairns J, Tewardy D, et al. Effect of granulocyte-colony-stimulating factor on lymphokine-activated killer cell induction. Blood. 1993;81:2671-2678.
15. Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. 1987;67:35-43.
16. Sanda M, Bolton E, Mule J, et al. In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-dependent cytotoxicity of tumor cells. J Immunother. 1992;12:132-137.
17. Ho A, Haas R, Wulf G, et al. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood. 1990;75:203-212.
18. Richard C, Alsar M, Calavia J, et al. Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies. Bone Marrow Transplant. 1993;11:473-478.
19. Schiller J, Hank J, Khorsand M, et al. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor co-administered with interleukin 2: a phase IB study. Clin Cancer Res. 1996;2:319-330.
20. Lieschke G, Burgess A. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med. 1992; 327:28-35.
21. Munn D, Cheung N. Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med. 1990;172:231-237.
22. Kleinerman E, Knowles R, Lachman L, et al. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res. 1988;48:2604-2609.
23. Ragnhammar P, Magnusson I, Masucci G, et al. The therapeutic use of the unconjugated monoclonal antibodies (Mab) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma. Med Oncol Tumor Pharmacother. 1993;10:61-70.
24. Tate J, Olenski T, Finke J, et al. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal cell carcinoma: clinical and laboratory effects. Ann Oncol. 2001;12:655-659.
25. Westermann J, Reich G, Kopp J, et al. Granulocyte-macrophage-colony- stimulating factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2001;49:613-620.
26. de Gast G, Klumpen H, Vyth-Dreese F, et al. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low dose interleukin 2 and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin Cancer Res. 2000;6:1267-1272.
27. Dutcher J, Caliendo G, Oleksowicz L, et al. Phase II study of moderate dose bolus IL-2 plus GM-CSF in metastatic renal cell cancer [abstract]. Proc Soc Biol Ther. 1997.
28. Dutcher J, Caliendo G, Novik Y, et al. Phase II study of moderate dose bolus or continuous infusion IL-2 plus GM-CSF in metastatic renal cell cancer [abstract 174O]. Proc Am Soc Clin Oncol. 1999;18:451a.
29. Dutcher JP, Fine JP, Krigel RL, et al. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of IFN-gamma plus/minus IFN-alpha in advanced renal cell carcinoma (E6890). Medical Oncology. 2003;20:271-281.
30. Vera N, Jansen R, Groenewegen G, et al. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and INF-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer. 2003;88:1346-1351.
31. Ryan C, Vogelzang N, Dumas M, et al. Granulocyte-macrophage colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer. 2000;88:1317-1324.
32. Schmidinger M, Steger G, Wenzel C, et al. Sequential administration of interferon gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: results of a phase H trial. J Immunother. 2001;24: 257-262.